FII favourite small-cap stock below ₹100 jumps over 4% from today's low. Do you own?
MIC Electronics reported a net profit of ₹ 3.57 crore for Q4FY25, marking a significant 92.84 percent drop from ₹ 49.59 crore in the corresponding quarter of the previous fiscal year. The steep decline in profits came as a surprise to investors, especially given the company's impressive topline performance. Total income for the quarter stood at ₹ 45.15 crore, up 89.5 percent from ₹ 23.82 crore in Q4FY24, reflecting a substantial increase in business activity.
On the operating front, the company reported a 37.74 percent rise in EBITDA to ₹ 8.65 crore, compared to ₹ 6.28 crore in the year-ago period, indicating improved operational efficiency and margin resilience despite bottom-line pressures.
For the full year ended March 2025, MIC Electronics' net profit fell 84.10 percent to ₹ 9.83 crore from ₹ 61.84 crore in FY24. However, total annual sales jumped 73.65 percent to ₹ 94.76 crore, compared to ₹ 54.57 crore in the previous fiscal, driven by broader market penetration and product demand.
While the drop in profit raises concerns about cost structures and possibly one-time adjustments, the sharp revenue growth signals robust order execution and customer expansion, especially in export markets.
Foreign & Promoter Holdings
Foreign Portfolio Investors (FPIs) held a 3.80 percent stake in MIC Electronics as of March 2025, slightly lower than the 4.15 percent held in the December 2024 quarter. However, the number of FPI investors increased from 7 to 12 during the period, reflecting broader institutional interest. Notably, Mauritius-based Multitude Growth Funds Limited acquired a 1.47 percent stake (3.55 million shares) in Q4FY25, highlighting strategic accumulation despite headline profit concerns.
Promoter confidence remains high, with their stake rising to 66.48 percent in March 2025, up from the previous quarter. This suggests long-term conviction in the company's growth strategy.
Founded in 1988, MIC Electronics has evolved into a key domestic player in LED display systems, telecom equipment, and medical devices. The company operates on a global scale, with presence in the USA, UK, and Australia. It has positioned itself as an innovation-driven, export-oriented manufacturer catering to government and industrial segments.
Over the past year, the stock has returned nearly 9 percent. It has gained 4.75 percent so far in May following a 6 percent rise in April. However, the stock had a rough start to 2025, slipping 5.5 percent in March, 31 percent in February, and 3.9 percent in January.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
23 minutes ago
- Business Standard
Aurobindo Pharma expects China plant to break even at Ebitda level in FY26
Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the Ebitda (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian said in an analyst call. He noted that around $145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about $70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to file for more than 20 products in the US and Europe from its Eugia-V plant in Visakhapatnam. He noted that the company has invested around $30 million in the Biologics CMO business so far, and the balance of $100 million plus capital is expected to be invested by March 2027. On business outlook, Subramanian stated: "Looking ahead, we remain optimistic about sustaining our growth momentum. Our confidence is supported by expected volume expansion, continued product launches and a stable pricing environment, especially in the US and Europe". Commercial operations ramping up at new manufacturing sites would further support the topline growth and margin improvement in the upcoming quarters, he added. "We are confident of achieving our internal target margin of 20-21 per cent in FY26," Subramanian stated. Aurobindo Pharma reported a 10 per cent year-on-year dip in its consolidated net profit to ₹824 crore for the June quarter, due to a fall in sales in the US and API business vertical. Its revenue from operations increased to ₹7,868 crore for the June quarter against ₹7,567 crore in the year-ago period.
Time of India
40 minutes ago
- Time of India
Pakistan wants to earn billions with its 'rare earth treasure' while walking US-China tightrope
Pakistan's Army Chief Asim Munir has said the country possesses a 'rare earth treasure' that could ease its debt burden and elevate it among prosperous nations, ANI reported citing Pakistan-based media. His remarks come at a time when rare earths have become central to global supply chain strategies, with China deploying them as a tool of economic leverage and the United States, India, and others scrambling to diversify access. In an interaction published by Jang media, Munir said, 'Pakistan has a rare earth treasure; with this treasure, Pakistan's debt will also be reduced, and Pakistan will soon be counted among the most prosperous societies.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Belly Fat Removal Without Surgery in Algeria: The Price Might Surprise You Belly Fat Removal | Search Ads Get Info He pointed specifically to the Reko Diq mining project in Balochistan, predicting that from next year Pakistan could earn at least $2 billion annually, with profits expected to rise year after year. China's dominance in rare earths as India in a tight spot China accounts for the bulk of global rare earth mining and nearly all refining capacity. Over the past year, Beijing has tightened export controls on minerals and high-performance magnets crucial for electric vehicles, defence systems and electronics. Live Events Also Read: Papum Pare to Singrauli- India maps fresh hotspots for rare earth metals amid China concerns In early 2025, it placed restrictions on shipments to the United States, forcing Washington into a temporary tariff truce. While some export curbs were relaxed, military-grade materials remain under control, leaving global industries wary. As for India, which imports over 70% of its rare earth requirements from China, has been exposed to these supply chain disruptions. Automakers such as Maruti Suzuki and Bajaj have reported hurdles in their EV plans, while electronics and machinery sectors have also faced pressure. Economists warn that prolonged shortages could ripple across multiple industries. To counter this, New Delhi is preparing a ₹5,000 crore scheme to ramp up domestic production and reduce dependence on Chinese imports. Against this backdrop, Munir is attempting to present Pakistan's mineral wealth as a strategic card. The U.S. factor The United States has stepped up efforts to secure alternative sources of critical minerals, viewing overreliance on China as a national security risk. Munir has visited the United States twice in the past few months for high-level engagements, underscoring a warmer phase in ties. On Pakistan's Independence Day, US Secretary of State Marco Rubio said Washington was keen to 'explore new areas of economic cooperation, including critical minerals and hydrocarbons.' His statement followed the announcement of a new trade agreement aimed at lowering tariffs and attracting US investment in Balochistan's mining projects. Also Read: US eyes critical minerals, hydrocarbons in fresh economic push with Pakistan Washington has also expanded energy cooperation with Islamabad, with Pakistan's largest refiner sealing a deal to import U.S. crude shipments as part of a wider oil deal. Furthermore, Trump has made overly optimistic claims about helping Pakistan to develop large oil reserves for potential exports. Last month, Donald Trump unveiled a 25% tariff on Indian imports while simultaneously announcing an oil partnership with Pakistan. 'We have just concluded a Deal with the Country of Pakistan, whereby Pakistan and the United States will work together on developing their massive Oil Reserves… Who knows, maybe they'll be selling Oil to India some day!' Trump wrote on Truth Social. These moves point to a broadening economic and strategic agenda between the two countries, where minerals could emerge as a new axis of cooperation. For Washington, Pakistan's rare earth potential is another incentive to deepen ties. The Washington Post earlier reported that US officials view Pakistan's untapped reserves as a hedge against Chinese dominance. However, for Munir & Pakistan government this will be an act of balancing global powers. Can Pakistan really make it happen? But Pakistan's strategic geography also ties it closely to Beijing. China is building a 2,000-mile transport network through northern Pakistan to a southern port, linking its Belt and Road Initiative to the Arabian Sea. At the same time, separatist violence in Balochistan, where Reko Diq is located, continues to target mining operations. The US recently designated the Balochistan Liberation Army (BLA) as a terrorist organisation, aligning with Islamabad's security concerns. Munir has publicly stated that Pakistan seeks equilibrium in its external relations. 'We will not sacrifice one friend for the other,' he was quoted as saying in Jang media, signalling a desire to balance ties with both the U.S. and China.
Mint
2 hours ago
- Mint
Aurobindo Pharma expects China plant to break even at EBITDA level this year
New Delhi, Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA level by Q3 FY26," Subramanian said in an analyst call. He noted that around USD 145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about USD 70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to file for more than 20 products in the US and Europe from its Eugia-V plant in Visakhapatnam. He noted that the company has invested around USD 30 million in the Biologics CMO business so far, and the balance of USD 100 million plus capital is expected to be invested by March 2027. On business outlook, Subramanian stated: "Looking ahead, we remain optimistic about sustaining our growth momentum. Our confidence is supported by expected volume expansion, continued product launches and a stable pricing environment, especially in the US and Europe". Commercial operations ramping up at new manufacturing sites would further support the topline growth and margin improvement in the upcoming quarters, he added. "We are confident of achieving our internal target margin of 20-21 per cent in FY26," Subramanian stated. Aurobindo Pharma reported a 10 per cent year-on-year dip in its consolidated net profit to ₹ 824 crore for the June quarter, due to a fall in sales in the US and I business vertical. Its revenue from operations increased to ₹ 7,868 crore for the June quarter against ₹ 7,567 crore in the year-ago period. This article was generated from an automated news agency feed without modifications to text.
